Live Breaking News & Updates on Ulka Nitin Vaishampayan

Stay updated with breaking news from Ulka nitin vaishampayan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dr Vaishampayan on the Rationale For the SWOG-1931/PROBE Trial in Advanced RCC

Ulka Nitin Vaishampayan, MBBS, discusses the rationale for conducting the phase 3 SWOG 1931 trial in patients with advanced renal cell carcinoma.
....

United States , Ulka Nitin Vaishampayan , University Of Michigan , Phasei Program At Rogel Cancer Center , International Kidney Cancer Symposium , Phasei Program , Rogel Cancer Center , Kidney Cancer Symposium , Onclive Tv , Genitourinary Cancer , Renal Cell Carcinoma ,

Dr Vaishampayan on the Use of Talazoparib and Enzalutamide in Patients With HRR Gene–Mutated mCRPC

Ulka Nitin Vaishampayan, MBBS, discusses the need for improved identification of patients with homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer who may benefit from treatment with talazoparib and enzalutamide. ....

United States , Ulka Nitin Vaishampayan , University Of Michigan , Rogel Cancer Center , Phasei Program , Talazoparib And Enzalutamide , Hrr Gene Mutated ,

Evaluation of Novel Agents and Combinations Aims to Improve Outcomes in Frontline RCC

Ulka Nitin Vaishampayan, MBBS, discusses factors to consider for choosing between immuno-oncology/immuno-oncology and VEGF TKI/immuno-oncology combinations for the frontline treatment of patients with renal cell carcinoma, areas of ongoing research in this disease, and treatment updates across the prostate cancer spectrum. ....

Ann Arbor , United States , Clara Hwang , Ulka Nitin Vaishampayan , Shawna Kraft , Sarah Yentz , Phasei Program , University Of Michigan Rogel Cancer Center , Rogel Cancer Center , University Of Michigan , Henry Ford Health , Science Summit , Michigan Rogel Cancer Center , Patients With Metastatic Renal Cell Carcinoma , The University Of Michigan , Treatment Updates Across Prostate Cancer ,

Dr Vaishampayan on Patient Considerations When Choosing Between FDA-Approved Therapies in nmCRPC

Ulka Nitin Vaishampayan, MBBS, discusses patient factors to consider when choosing between apalutamide, enzalutamide, and darolutamide for the treatment of patients with non-metastatic castration resistant prostate cancer.
....

United States , Ulka Nitin Vaishampayan , Phasei Program , Rogel Cancer Center , University Of Michigan , Onclive Tv , Non Metastatic Castration Resistant Prostate Cancer ,

Dr Vaishampayan on Toxicities Associated With Various Treatments in RCC

Dr Vaishampayan on Toxicities Associated With Various Treatments in RCC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

United States , Ulka Nitin Vaishampayan , Phasei Program At Rogel Cancer Center , University Of Michigan , Phasei Program , Rogel Cancer Center ,